83 filings
8-K
EQ
Equillium Inc
23 May 24
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
EQ
Equillium Inc
9 May 24
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
4:05pm
8-K
EQ
Equillium Inc
1 Apr 24
Other Events
8:05am
8-K
EQ
Equillium Inc
25 Mar 24
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
4:05pm
8-K
EQ
Equillium Inc
8 Mar 24
Departure of Directors or Certain Officers
4:01pm
8-K
n47hk 751tsn
23 Feb 24
Results of Operations and Financial Condition
5:12pm
8-K
z16n1
22 Feb 24
Other Events
6:08am
8-K
xh3huj4r7ub0rfzhc
21 Dec 23
Other Events
8:05am
8-K
xdvd0xl6go02k4bb
8 Nov 23
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
4:05pm
8-K
ujv61fm098ragocywjc
16 Oct 23
Regulation FD Disclosure
8:05am
8-K
wqhknp6v t01b3
5 Oct 23
Entry into a Material Definitive Agreement
5:28pm
8-K
pjtl9tbyo2kyj8237k
9 Aug 23
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
4:06pm
8-K
gq6a0tw
25 May 23
Termination of a Material Definitive Agreement
4:00pm
8-K
k99frw1bq
23 May 23
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
najolb xnv47vrgr
11 May 23
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates
4:06pm
8-K
vouden67
6 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:02pm
8-K
rlc5vpcdlg 6r4yqc
23 Mar 23
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides CorporateĀ & Clinical Development Updates
4:05pm
8-K
l0108iezn8fe z17ef8
23 Dec 22
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
4:11pm
8-K
v7clkkvgturpyf11pmyl
14 Dec 22
Other Events
9:49pm
8-K
jax5jx5eo49ugx
6 Dec 22
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
7:00am